This news article is based on a press release statement from Axsome Therapeutics (NASDAQ:AXSM). The company continues to focus on addressing critical gaps in CNS treatment and advancing patient ...

Axsome Therapeutics, Inc. AXSM announced that the FDA has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults. Per the company ...

Axsome Therapeutics has finally jumped all the hurdles in a challenging regulatory saga, winning approval for its oral migraine drug Symbravo. The rapid-acting treatment is approved for the acute ...

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...

Analyst Vikram Purohit of Morgan Stanley maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), retaining the price target of $125.00. Vikram Purohit’s rating is based on ...

H.C. Wainwright raised the firm’s price target on Axsome Therapeutics (AXSM) to $190 from $180 and keeps a Buy rating on the shares. The firm says AXS-07 approval in acute treatment of migraine ...

The FDA has approved Axsome Therapeutics’ Symbravo (meloxicam and rizatriptan), a novel acute treatment for adults with migraine with or without aura. According to the company, Symbravo employs Axsome ...

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will ...